PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'KARE Biosciences, Orange, CA, USA.\', \'Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD, USA.\', \'Arizona State University, Edson College, Phoenix, AZ, USA.\', \'North Carolina State University, Raleigh, NC, USA.\', \'Department of Pediatric Hematology and Oncology, Yale School of Medicine, New Haven, CT, USA.\', \'Rutgers University, New Jersey Medical School and Public Health Research Institute, Newark, NJ, USA.\', \'Drug Discovery Center and Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, USA.\', \'Department of Pathology and Laboratory Medicine, the University of California at Davis, Sacramento, CA, USA.\', \'Departments of Medicine, and Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.\', \'Molecular Toxicology Interdepartmental Degree Program, UCLA, Los Angeles, CA, USA.\', \'Charak Foundation, Orange, CA.\', \'Division of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine, Orange, CA, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/14728222.2022.2031975
?:doi
?:hasPublicationType
?:journal
  • Expert opinion on therapeutic targets
is ?:pmid of
?:pmid
?:pmid
  • 35068281
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.597
?:rankingScore_hIndex
  • 74
is ?:relation_isRelatedTo_publication of
?:title
  • Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all